Q3 EPS Forecast for Jasper Therapeutics Reduced by Analyst

Key Takeaways:

• William Blair reduced its Q3 2025 EPS estimate for Jasper Therapeutics.
• Analyst M. Phipps now expects a loss of $0.75 per share.
• The revised figure is lower than the firm’s earlier projection.
• The analyst report was released on Thursday, August 14.
• Defenseworld.net summarized the downgrade on August 18.

Lead
A fresh analyst note is injecting new uncertainty into Jasper Therapeutics’ near-term fortunes. On August 14, William Blair’s M. Phipps lowered the biotech firm’s third-quarter 2025 earnings-per-share (EPS) projection to –$0.75, a sharper loss than previously anticipated. Defenseworld.net relayed the downgrade four days later.

The New Number
The revised figure—negative seventy-five cents per share—stands as the latest signal that Jasper’s path to profitability remains steep. While William Blair did not publicly disclose its earlier estimate in the summary obtained by Defenseworld.net, the brokerage made clear that the new outlook represents a decline “from their prior forecast.”

Inside the Analyst Note
Analyst revisions can move markets, and William Blair’s update carries the weight of its research reputation. The August 14 report, succinctly captured by Defenseworld.net, stated: “William Blair cut their Q3 2025 earnings per share estimates for Jasper Therapeutics.” M. Phipps’ call underscores a view that Jasper’s third-quarter performance may fall short of earlier hopes.

What It Means for Jasper
For Jasper Therapeutics—listed on Nasdaq under the ticker JSPR—the deeper projected loss adds pressure ahead of its next earnings release. Investors monitoring early-stage biotech firms often lean heavily on analyst guidance to gauge risk, and a shift of this magnitude can sharpen scrutiny.

Looking Ahead
With the calendar marching toward the third quarter’s close, questions about Jasper’s financial trajectory will remain unresolved until the company reports actual results. Until then, William Blair’s –$0.75 call will likely serve as the benchmark against which investors judge the company’s progress—or lack thereof.